Halozyme Therapeutics Inc (HALO) Stock Analysis

Halozyme Therapeutics Inc (HALO) is a publicly traded company in the HEALTHCARE sector. It trades at $66.28, carries a market capitalization of $8.08B, a price-to-earnings ratio of 23.91. This page summarizes the public market data, fundamentals, and frequently asked questions for HALO, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Halozyme Therapeutics Inc currently has a Bullish sentiment score of 0.33.

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc. is an innovative biopharmaceutical company headquartered in San Diego, California, recognized for its groundbreaking drug delivery technologies that significantly enhance the effectiveness of existing therapies. Utilizing its proprietary ENHANZE® technology, Halozyme focuses on developing subcutaneous formulations that improve patient adherence and outcomes across a range of indications. The company strategically collaborates with industry-leading pharmaceutical pa...

GNG Research Analysis

GNG Research scores Halozyme Therapeutics Inc (HALO) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for HALO.

Frequently Asked Questions

Does HALO pay dividends?

Halozyme Therapeutics Inc (HALO) does not currently pay a regular dividend.

What is HALO's P/E ratio?

Halozyme Therapeutics Inc has a price-to-earnings (P/E) ratio of 23.91.

What is HALO's market cap?

Halozyme Therapeutics Inc (HALO) has a market capitalization of $8.08B with a current stock price of $66.28.